Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sunshine Biopharma Inc.SBFM · Entity 8329 | Director · Chief Executive Officer · 10% owner | March 04, 2024 | March 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sunshine Biopharma Inc.
Report date March 04, 2024 · Filed March 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series B Preferred StockSEC Table I · non-derivative | Direct | 130,000 |
Reported balance
After 2024-03-04 transaction · row 1
1 source rowRow 1 · 2024-03-04 · Purchase · Acquired 100,000 · Balance 130,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2024 Filed Mar 5, 2024 16:05 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | PurchaseSeries B Preferred Stock | 100,000 | $0.10 | $10,000.00 |
DisclosureSEC source: 0001683168-24-001322 · ownership.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 16:05 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | PurchaseSeries B Preferred Stock | 20,000 | $0.10 | $2,000.00 |
DisclosureSEC source: 0001683168-24-000879 · ownership.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 13:07 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | Disposition to issuerSeries B Preferred Stock | 990,000 | $0.10 | $99,000.00 |
DisclosureSEC source: 0001683168-22-001185 · ownership.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: Dr. Slilaty returned 990,000 shares of Series B Preferred Stock to the Issuer for a redemption price equal to the stated value of $0.10 per share. Read SEC document |
| January 06, 2021 Filed Feb 16, 2021 12:30 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 20,000,000 | $0.00 | $20,000.00 |
DisclosureSEC source: 0001128732-21-000002 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,343,461 Read SEC document |
| June 17, 2020 Filed Jun 25, 2020 14:19 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantSeries "B" Preferred Stock | 500,000 | $0.10 | $50,000.00 |
DisclosureSEC source: 0001128732-20-000002 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Read SEC document |
| December 31, 2019 Filed Jul 10, 2020 13:26 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | OtherCommon Stock | 323,673 | $0.00 | $323.67 |
DisclosureSEC source: 0001128732-20-000003 · primary_doc.xml · nonDerivative · entry 3 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by TRT Pharma Inc., an entity controlled by the Reporting Person. Disclosed balance after: 861,209 F2 · kind: Effective December 31, 2019, Advanomics Corporation, a entity controlled by the Reporting Person, effectuated a consolidation with 4019318 Canada, Inc., an entity controlled by the Chief Financial Officer of the Issuer. The resulting consoildated entity changed its name to TRT Pharma Inc. The consolidation resulted in the transfer of 323,673 shares of post-reverse splits of the Issuer's Common Stock to TRT Pharma Inc. of which the Reporting Person is a control person. F1 · shares: The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F2 · ownership.nature: Effective December 31, 2019, Advanomics Corporation, a entity controlled by the Reporting Person, effectuated a consolidation with 4019318 Canada, Inc., an entity controlled by the Chief Financial Officer of the Issuer. The resulting consoildated entity changed its name to TRT Pharma Inc. The consolidation resulted in the transfer of 323,673 shares of post-reverse splits of the Issuer's Common Stock to TRT Pharma Inc. of which the Reporting Person is a control person. Read SEC document |
| December 19, 2019 Filed Jul 10, 2020 13:26 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 1,300,000 | $0.00 | $1,300.00 |
DisclosureSEC source: 0001128732-20-000003 · primary_doc.xml · nonDerivative · entry 2 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,343,461 F1 · shares: The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. Read SEC document |
| October 20, 2019 Filed Jul 10, 2020 13:26 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 1,100,000 | $0.00 | $1,100.00 |
DisclosureSEC source: 0001128732-20-000003 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,043,461 F1 · shares: The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. F1 · balance_after: The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. Read SEC document |
| September 02, 2019 Filed Sep 23, 2019 09:45 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 13,000,000 | $0.00 | $13,000.00 |
DisclosureSEC source: 0001128732-19-000024 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,869,219 F1 · balance_after: Effective February 1, 2019, the Issuer effectuated a reverse stock split wherein 1 share of Common Stock was issued for each 20 shares of the issued and outstanding Common Stock of the Issuer resulting in Reporting Person owning 5,869,219 shares of Common Stock of the Issuer as of that date. Read SEC document |
| August 27, 2018 Filed Sep 14, 2018 10:08 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 38,000,000 | $0.00 | $38,000.00 |
DisclosureSEC source: 0001128732-18-000011 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,384,373 Read SEC document |
| June 20, 2018 Filed Jun 28, 2018 17:47 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 27,000,000 | $0.00 | $27,000.00 |
DisclosureSEC source: 0001128732-18-000006 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,384,373 Read SEC document |
| July 20, 2017 Filed Sep 8, 2017 09:28 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 14,000,000 | $0.00 | $14,000.00 |
DisclosureSEC source: 0001128732-17-000031 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,384,373 Read SEC document |
| December 06, 2016 Filed Dec 15, 2016 19:45 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | GrantCommon Stock | 26,000,000 | $0.00 | $26,000.00 |
DisclosureSEC source: 0001128732-16-000036 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,384,373 Read SEC document |
| October 10, 2016 Filed Nov 7, 2016 11:41 UTC | Sunshine Biopharma Inc. SBFM · Entity 8329 | OtherCommon Stock | 136,861,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001128732-16-000030 · primary_doc.xml · nonDerivative · entry 1 Slilaty Steve N. · CIK 0001474684 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Advanomics Corporation, an entity controlled by Reporting Person. Disclosed balance after: 215,014,224 F1 · kind: 136,861,968 shares owned by Advanomics Corporation, an entity controlled by Reporting Person, were disposed of pursuant to a share exchange with an unrelated party; no consideration was received as a result of the share exchange. F1 · price: 136,861,968 shares owned by Advanomics Corporation, an entity controlled by Reporting Person, were disposed of pursuant to a share exchange with an unrelated party; no consideration was received as a result of the share exchange. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.